These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8128836)

  • 1. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG.
    Minthon L; Gustafson L; Dalfelt G; Hagberg B; Nilsson K; Risberg J; Rosén I; Seiving B; Wendt PE
    Dementia; 1993; 4(1):32-42. PubMed ID: 8358504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease.
    Minthon L; Nilsson K; Edvinsson L; Wendt PE; Gustafson L
    Dementia; 1995; 6(5):245-51. PubMed ID: 8528370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
    Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
    Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB.
    Sahakian BJ; Coull JT
    Acta Neurol Scand Suppl; 1993; 149():29-35. PubMed ID: 8128835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease.
    Alhainen K; Partanen J; Reinikainen K; Laulumaa V; Soininen H; Airaksinen M; Riekkinen P
    Neurosci Lett; 1991 Jun; 127(1):113-6. PubMed ID: 1881606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients.
    Alhainen K; Helkala EL; Riekkinen P
    Dementia; 1993; 4(1):54-8. PubMed ID: 8358507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results.
    Boller F; Forette F
    Biomed Pharmacother; 1989; 43(7):487-91. PubMed ID: 2684292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease.
    Riekkinen P; Riekkinen M; Soininen H; Kuikka J; Laakso M; Riekkinen P
    Neuroreport; 1997 May; 8(8):1845-9. PubMed ID: 9223063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
    Håkansson L
    Acta Neurol Scand Suppl; 1993; 149():7-9. PubMed ID: 7907455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
    Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
    N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physostigmine reversal of scopolamine-induced hypofrontality.
    Prohovnik I; Arnold SE; Smith G; Lucas LR
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):220-8. PubMed ID: 9040502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EEG regional changes during long-term treatment with tetrahydroaminoacridine (THA) in Alzheimer's disease.
    Shigeta M; Persson A; Viitanen M; Winblad B; Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():58-61. PubMed ID: 8128842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease.
    Perryman KM; Fitten LJ
    J Geriatr Psychiatry Neurol; 1991; 4(3):127-33. PubMed ID: 1953964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
    Mesulam MM; Geula C; Morán MA
    Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET.
    Nordberg A
    Acta Neurol Scand Suppl; 1993; 149():62-5. PubMed ID: 8128843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.